AIM ImmunoTech Inc.
AIM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -15.8% | 43.3% | 4.4% | – |
| Cost of Goods Sold | $0 | $0 | -$0 | $1 |
| Gross Profit | $0 | $0 | $1 | -$1 |
| % Margin | 81.8% | 79.2% | 400.7% | -529.6% |
| R&D Expenses | $6 | $11 | $7 | $8 |
| G&A Expenses | $14 | $21 | $0 | $9 |
| SG&A Expenses | $14 | $21 | $13 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $20 | $32 | $20 | $18 |
| Operating Income | -$20 | -$32 | -$20 | -$19 |
| % Margin | -11,630.6% | -15,800% | -14,129.7% | -13,954.1% |
| Other Income/Exp. Net | $2 | $3 | $0 | -$0 |
| Pre-Tax Income | -$17 | -$29 | -$19 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$29 | -$19 | -$19 |
| % Margin | -10,188.2% | -14,337.6% | -13,790.8% | -14,168.1% |
| EPS | -0.31 | -0.6 | -0.44 | -0.45 |
| % Growth | 48.3% | -36.4% | 2.2% | – |
| EPS Diluted | -0.31 | -0.6 | -0.44 | -0.45 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $0 | $1 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $1 |
| EBITDA | -$16 | -$29 | -$20 | -$18 |
| % Margin | -9,699.4% | -14,219.8% | -14,091.5% | -13,544.4% |